ARTL - Artelo Biosciences Inc logo

ARTL

Artelo Biosciences Inc

Rev โ€”top 1%5Y
Hold

Artelo Biosciences develops therapeutics targeting lipid-signaling pathways, with a pipeline including drugs for cancer-related anorexia, anxiety, and neuropathic pain. Its product candidates aim to address unmet medical needs across various conditions.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 5 years ago โ†’$3today

Score Overview

1 Year
Scoreโ€”
Net Growth-4.55%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-81.05%
Net Trend20%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-55x
Net Trend22%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Artelo Biosciences Inc fundamental performance

Across Artelo Biosciences Inc's full reported history, from 2017 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 234.89K to -$ 12M. Revenue increased in 0% of the years measured; net income in 22%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-13
$ 0.76โ€”
1 Year2025-08-13
$ 30.39-97.50%
5 Years2021-08-13
$ 234.36-99.68%
All Time2017-11-14
$ 4.00-81.03%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 13M$ 10M
2025$ 0.00-$ 12M$ 600K
2024$ 0.00-$ 9M$ 2M
2023$ 0.00-$ 9M$ 10M
2022$ 0.00-$ 10M$ 17M
2021$ 0.00-$ 7M$ 10M
2020$ 0.00-$ 4M$ 2M
2019$ 0.00-$ 2M$ 4M
2018$ 0.00-$ 2M$ 337.42K
IPO2017$ 0.00-$ 234.89K$ 572.77K

Explore beyond ARTL

You're looking at Artelo Biosciences Inc. Members apply the same fundamental framework across all 3,859 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies